NEW YORK (GenomeWeb) – MDxHealth today announced that Tufts Health Plan will provide its more than 1 million members with access to the firm's ConfirmMDx test for prostate cancer.

The agreement covers Tufts' government and commercial programs and products. Financial and other details were not disclosed.

ConfirmMDx for Prostate Cancer detects the methylation status of biomarkers associated with the cancer development process, identifying patients who many not need a repeat biopsy following a negative result.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.